Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack

Cancer Gene Therapy volume 10, pages 870–878 (2003)Cite this article

Abstract

Data presented here demonstrate that vaccine-induced CD8+ T cells can eliminate their specific tumor-target with a two-staged attack. First, they release interferon-γ that results in growth arrest of the tumor cells via induction of antiangiogenic mediators. Then, during the latter stages of the immune response, CD8+ effector T cells eradicate the remaining tumor cells through perforin-mediated lysis. A combination of these two mechanisms is highly effective in the described model, while either pathway alone fails to completely achieve tumor rejection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95:7556–7561.

    Article  CAS  Google Scholar 

  2. Gallucci S, Matzinger P . Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13:114–119.

    Article  CAS  Google Scholar 

  3. Wang RF, Rosenberg SA . Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85–100.

    Article  CAS  Google Scholar 

  4. He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology. 2000;270:146–161.

    Article  CAS  Google Scholar 

  5. Rothstein TL, Mage M, Jones G, et al. Cytotoxic T lymphocyte sequential killing of immobilized allogeneic tumor target cells measured by time-lapse microcinematography. J Immunol. 1978;121:1652–1656.

    CAS  PubMed  Google Scholar 

  6. Guidotti LG, Chisari FV . Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65–91.

    Article  CAS  Google Scholar 

  7. Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, et al. A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Meth.. 2001;253:163–175.

    Article  CAS  Google Scholar 

  8. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–26.

    CAS  PubMed  Google Scholar 

  9. Kleinman HK, McGarvey ML, Liotta LA, et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry. 1982;21:6188–6193.

    Article  CAS  Google Scholar 

  10. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992;67:519–528.

    CAS  PubMed  Google Scholar 

  11. Vicari AP, Ait-Yahia S, Chemin K, et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165:1992–2000.

    Article  CAS  Google Scholar 

  12. Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest. 2001;107:53–63.

    Article  CAS  Google Scholar 

  13. Salcedo R, Resau JH, Halverson D, et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000;14:2055–2064.

    Article  CAS  Google Scholar 

  14. Qin Z, Blankenstein T . CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12:677–686.

    Article  CAS  Google Scholar 

  15. Beatty G, Paterson Y . IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol. 2001;166:2276–2282.

    Article  CAS  Google Scholar 

  16. Angiolillo AL, Sgadari CTosato G . A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci. 1996;795:158–167.

    Article  CAS  Google Scholar 

  17. Weston SA, Parish CR . New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Meth. 1990;133:87–97.

    Article  CAS  Google Scholar 

  18. Gudmundsdottir H, Wells AD, Turka LA . Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol. 1999;162:5212–5223.

    CAS  PubMed  Google Scholar 

  19. Seliger B, Killian M, Pfizenmaier K . Distinct mechanisms of interferon-gamma and tumor necrosis factor-alpha action in oncogene-transformed mouse fibroblasts. J Cell Chem. 1988;38:205–212.

    CAS  Google Scholar 

  20. Emilie D, Maillot MC, Nicolas JF, et al. Antagonistic effect of interferon-gamma on tat-induced transactivation of HIV long terminal repeat. J Biol Chem. 1992;267:20565–20570.

    CAS  PubMed  Google Scholar 

  21. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995;55:4140–4145.

    CAS  PubMed  Google Scholar 

  22. Peoples GE, Blotnick S, Takahashi K, et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA. 1995;92:6547–6551.

    Article  CAS  Google Scholar 

  23. Kotecha MT, Afghan RK, Vasilikopoulou E, et al. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. Vaccine. 2003;21:2506–2515.

    Article  CAS  Google Scholar 

  24. Xiang ZQ, Yang Y, Wilson JM, et al. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 1996;219:220–227.

    Article  CAS  Google Scholar 

  25. Kowalczyk DW, Wlazlo AP, Giles-Davis W, et al. Staining of antigen activated lymphocytes (SAAL): a highly specific method for flow cytometric quantitation of tumor-specific CD8(+) T cells. J Immunol Meth. 2000;241:131–139.

    Article  CAS  Google Scholar 

  26. Blaszczyk-Thurin M, O I, Ertl HC . An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Scand J Immunol. 2002;56:361–375.

    Article  CAS  Google Scholar 

  27. Vierboom MP, Feltkamp MC, Neisig A, et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother. 1998;21:399–408.

    Article  CAS  Google Scholar 

  28. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 1997;186:695–704.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Dariusz W Kowalczyk and Anthony P Wlazlo: Both authors contributed equally to this manuscript.

Authors and Affiliations

  1. Department of Cancer Immunology, Greatpoland Cancer Center, Garbary 15, Poznan, 61-866, Poland

    Dariusz W Kowalczyk

  2. The Wistar Institute, Philadelphia, 19104, Pennsylvania, USA

    Anthony P Wlazlo, Wynetta Giles-Davis, Andreas R Kammer & Hildegund CJ Ertl

  3. Pevion Biotech Ltd., Bern, 3018, Switzerland

    Andreas R Kammer

  4. Amersham Biosciences, Piscataway, New Jersey, USA

    Sunil Mukhopadhyay

Authors
  1. Dariusz W Kowalczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony P Wlazlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wynetta Giles-Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas R Kammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sunil Mukhopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hildegund CJ Ertl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hildegund CJ Ertl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kowalczyk, D., Wlazlo, A., Giles-Davis, W. et al. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther 10, 870–878 (2003). https://doi.org/10.1038/sj.cgt.7700653

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700653

Keywords

This article is cited by

Search

Advanced search

Quick links